Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing

The Food and Drug Administration cleared Intellia Therapeutics (NTLA) to begin testing its CRISPR gene-editing technology in people on Thursday, leading NTLA stock to jump.